JP2010525813A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010525813A5 JP2010525813A5 JP2010506206A JP2010506206A JP2010525813A5 JP 2010525813 A5 JP2010525813 A5 JP 2010525813A5 JP 2010506206 A JP2010506206 A JP 2010506206A JP 2010506206 A JP2010506206 A JP 2010506206A JP 2010525813 A5 JP2010525813 A5 JP 2010525813A5
- Authority
- JP
- Japan
- Prior art keywords
- oligonucleotide strand
- nucleotides
- nucleic acid
- length
- oligonucleotide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108091034117 Oligonucleotide Proteins 0.000 claims 29
- 125000003729 nucleotide group Chemical group 0.000 claims 27
- 239000002773 nucleotide Substances 0.000 claims 17
- 108020004707 nucleic acids Proteins 0.000 claims 12
- 150000007523 nucleic acids Chemical class 0.000 claims 12
- 102000039446 nucleic acids Human genes 0.000 claims 12
- 238000000034 method Methods 0.000 claims 6
- 230000000295 complement effect Effects 0.000 claims 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 3
- 230000014509 gene expression Effects 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 claims 3
- 239000005547 deoxyribonucleotide Substances 0.000 claims 2
- 125000002637 deoxyribonucleotide group Chemical group 0.000 claims 2
- 210000004962 mammalian cell Anatomy 0.000 claims 2
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims 2
- 125000002652 ribonucleotide group Chemical group 0.000 claims 2
- 230000002194 synthesizing effect Effects 0.000 claims 2
- 238000000137 annealing Methods 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/797,216 US20070265220A1 (en) | 2004-03-15 | 2007-05-01 | Methods and compositions for the specific inhibition of gene expression by double-stranded RNA |
| PCT/US2008/004726 WO2008136902A1 (en) | 2007-05-01 | 2008-04-11 | Methods and compositions for the specific inhibition of gene expression by double-stranded rna |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010525813A JP2010525813A (ja) | 2010-07-29 |
| JP2010525813A5 true JP2010525813A5 (enExample) | 2011-11-17 |
Family
ID=39944357
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010506206A Pending JP2010525813A (ja) | 2007-05-01 | 2008-04-11 | 二本鎖ｒｎａによる遺伝子発現の特異的阻害のための、方法及び組成物 |
Country Status (9)
| Country | Link |
|---|---|
| US (11) | US20070265220A1 (enExample) |
| EP (1) | EP2155772A4 (enExample) |
| JP (1) | JP2010525813A (enExample) |
| CN (1) | CN101848923A (enExample) |
| AU (1) | AU2008246307A1 (enExample) |
| BR (1) | BRPI0811475A2 (enExample) |
| CA (1) | CA2685453A1 (enExample) |
| WO (1) | WO2008136902A1 (enExample) |
| ZA (1) | ZA200908342B (enExample) |
Families Citing this family (113)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3222725A1 (en) | 2002-08-05 | 2017-09-27 | Silence Therapeutics GmbH | Further novel forms of interfering rna molecules |
| US7892793B2 (en) * | 2002-11-04 | 2011-02-22 | University Of Massachusetts | Allele-specific RNA interference |
| US7459547B2 (en) | 2003-06-02 | 2008-12-02 | University Of Massachusetts | Methods and compositions for controlling efficacy of RNA silencing |
| EP1633890B2 (en) * | 2003-06-02 | 2020-11-18 | University of Massachusetts | METHODS AND COMPOSITIONS FOR ENHANCING THE EFFICACY AND SPECIFICITY OF FNAi |
| US7750144B2 (en) * | 2003-06-02 | 2010-07-06 | University Of Massachusetts | Methods and compositions for enhancing the efficacy and specificity of RNA silencing |
| DK2821085T3 (da) * | 2003-09-12 | 2020-08-03 | Univ Massachusetts | Rna-interferens til behandling af "gain-of-function"-forstyrrelser |
| US8680063B2 (en) | 2003-09-12 | 2014-03-25 | University Of Massachusetts | RNA interference for the treatment of gain-of-function disorders |
| US20060134787A1 (en) * | 2004-12-22 | 2006-06-22 | University Of Massachusetts | Methods and compositions for enhancing the efficacy and specificity of single and double blunt-ended siRNA |
| US20070265220A1 (en) * | 2004-03-15 | 2007-11-15 | City Of Hope | Methods and compositions for the specific inhibition of gene expression by double-stranded RNA |
| AU2005222965B8 (en) | 2004-03-15 | 2010-07-01 | City Of Hope | Methods and compositions for the specific inhibition of gene expression by double-stranded RNA |
| EP2239328A3 (en) * | 2005-08-18 | 2011-01-05 | Alnylam Pharmaceuticals Inc. | Methods and compositions for treating neurological disease |
| LT2056845T (lt) | 2006-08-08 | 2017-11-27 | Rheinische Friedrich-Wilhelms-Universität Bonn | 5` fosfato oligonukleotidų struktūra ir panaudojimas |
| WO2008143774A2 (en) * | 2007-05-01 | 2008-11-27 | University Of Massachusetts | Methods and compositions for locating snp heterozygosity for allele specific diagnosis and therapy |
| EP2297323A1 (en) | 2008-05-21 | 2011-03-23 | Hartmann, Gunther | 5' triphosphate oligonucleotide with blunt end and uses thereof |
| TWI455944B (zh) | 2008-07-01 | 2014-10-11 | Daiichi Sankyo Co Ltd | 雙股多核苷酸 |
| WO2010021718A1 (en) | 2008-08-19 | 2010-02-25 | Nektar Therapeutics | Complexes of small-interfering nucleic acids |
| US8225729B2 (en) * | 2008-12-16 | 2012-07-24 | Kimberly-Clark Worldwide, Inc. | Three-dimensional wiping substrate and method therefor |
| KR101728655B1 (ko) * | 2008-12-18 | 2017-04-19 | 다이서나 파마수이티컬, 인크. | 유전자 발현의 특이적 억제를 위한 연장된 다이서 기질 제제 및 방법 |
| US20100249214A1 (en) | 2009-02-11 | 2010-09-30 | Dicerna Pharmaceuticals | Multiplex dicer substrate rna interference molecules having joining sequences |
| US11414664B2 (en) | 2008-12-18 | 2022-08-16 | Dicerna Pharmaceuticals, Inc. | Extended dicer substrate agents and methods for the specific inhibition of gene expression |
| WO2010111471A2 (en) * | 2009-03-27 | 2010-09-30 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 1 (STAT1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| EP2756845B1 (en) * | 2009-04-03 | 2017-03-15 | Dicerna Pharmaceuticals, Inc. | Methods and compositions for the specific inhibition of KRAS by asymmetric double-stranded RNA |
| PL3199165T3 (pl) * | 2009-04-03 | 2022-09-05 | Dicerna Pharmaceuticals, Inc. | Sposoby i kompozycje do specyficznego hamowania kras przez asymetryczne dwuniciowe rna |
| CA2762524A1 (en) * | 2009-05-18 | 2011-01-13 | Ensysce Biosciences, Inc. | Carbon nanotubes complexed with multiple bioactive agents and methods related thereto |
| WO2010141933A1 (en) * | 2009-06-05 | 2010-12-09 | Dicerna Pharmaceuticals, Inc. | Specific inhibition of gene expression by nucleic acid containing a dicer substrate |
| CN102803496A (zh) | 2009-06-10 | 2012-11-28 | 淡马锡生命科学研究院有限公司 | 用于棉花中基因功能性分析的病毒诱导的基因沉默(vigs) |
| JP5766188B2 (ja) | 2009-07-01 | 2015-08-19 | プロチバ バイオセラピューティクス インコーポレイティッド | 固形腫瘍に治療剤を送達するための脂質製剤 |
| US8716464B2 (en) | 2009-07-20 | 2014-05-06 | Thomas W. Geisbert | Compositions and methods for silencing Ebola virus gene expression |
| US8916693B2 (en) | 2009-09-17 | 2014-12-23 | Nektar Therapeutics | Monoconjugated chitosans as delivery agents for small interfering nucleic acids |
| US9222086B2 (en) | 2009-09-23 | 2015-12-29 | Protiva Biotherapeutics, Inc. | Compositions and methods for silencing genes expressed in cancer |
| KR101718534B1 (ko) | 2009-12-09 | 2017-03-22 | 닛토덴코 가부시키가이샤 | Ｈｓｐ４７ 발현의 조절 |
| WO2011072292A2 (en) * | 2009-12-11 | 2011-06-16 | Dicerna Pharmaceuticals, Inc. | Phase changing formulations of rna and rna derivatives |
| JP5257796B2 (ja) * | 2009-12-28 | 2013-08-07 | 株式会社村田製作所 | 固体電解コンデンサ素子及びその製造方法 |
| DK3587579T3 (da) | 2010-07-06 | 2021-04-26 | Dicerna Pharmaceuticals Inc | Fremgangsmåder og sammensætninger til specifik hæmning af beta-catenin ved hjælp af dobbeltstrenget rna |
| CA2804210A1 (en) | 2010-07-06 | 2012-01-12 | Dicerna Pharmaceuticals, Inc. | Methods and compositions for the specific inhibition of androgen receptor by double-stranded rna |
| CA2807552A1 (en) | 2010-08-06 | 2012-02-09 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| PL3590949T3 (pl) | 2010-10-01 | 2022-08-29 | Modernatx, Inc. | Kwasy rybonukleinowe zawierające n1-metylo-pseudouracyle i ich zastosowania |
| US20140134231A1 (en) | 2010-10-11 | 2014-05-15 | Sanford-Burnham Medical Research Institute | Mir-211 expression and related pathways in human melanoma |
| WO2012056440A1 (en) * | 2010-10-28 | 2012-05-03 | Nanodoc Ltd. | COMPOSITIONS AND METHODS FOR ACTIVATING EXPRESSION BY A SPECIFIC ENDOGENOUS miRNA |
| WO2012118910A2 (en) | 2011-03-03 | 2012-09-07 | Quark Pharmaceuticals, Inc. | Compositions and methods for treating lung disease and injury |
| EP2508530A1 (en) | 2011-03-28 | 2012-10-10 | Rheinische Friedrich-Wilhelms-Universität Bonn | Purification of triphosphorylated oligonucleotides using capture tags |
| DE12722942T1 (de) | 2011-03-31 | 2021-09-30 | Modernatx, Inc. | Freisetzung und formulierung von manipulierten nukleinsäuren |
| CN104245938B (zh) | 2011-06-10 | 2018-06-01 | 淡马锡生命科学研究院有限公司 | 用于柄锈菌亚门和黑粉菌亚门的基因操作和表达系统 |
| WO2012173994A2 (en) * | 2011-06-15 | 2012-12-20 | Dicerna Pharmaceuticals, Inc. | Phase changing formulations of nucleic acid payloads |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| RS62993B1 (sr) | 2011-10-03 | 2022-03-31 | Modernatx Inc | Modifikovani nukleozidi, nukleotidi, i nukleinske kiseline, i njihove upotrebe |
| ES2745373T3 (es) | 2011-10-18 | 2020-03-02 | Dicerna Pharmaceuticals Inc | Lípidos catiónicos de amina y uso de los mismos |
| IN2014CN03465A (enExample) | 2011-11-18 | 2015-10-09 | Alnylam Pharmaceuticals Inc | |
| PT2791160T (pt) | 2011-12-16 | 2022-07-04 | Modernatx Inc | Composições arnm modificado |
| US9035039B2 (en) | 2011-12-22 | 2015-05-19 | Protiva Biotherapeutics, Inc. | Compositions and methods for silencing SMAD4 |
| AU2013222179B2 (en) | 2012-02-24 | 2017-08-24 | Arbutus Biopharma Corporat ion | Trialkyl cationic lipids and methods of use thereof |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| AU2013243955B2 (en) | 2012-04-02 | 2018-02-22 | Modernatx, Inc. | Modified polynucleotides for the production of oncology-related proteins and peptides |
| US10501512B2 (en) | 2012-04-02 | 2019-12-10 | Modernatx, Inc. | Modified polynucleotides |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| IN2014KN02312A (enExample) | 2012-04-19 | 2015-05-01 | Temasek Life Sciences Lab Ltd | |
| WO2014018375A1 (en) | 2012-07-23 | 2014-01-30 | Xenon Pharmaceuticals Inc. | Cyp8b1 and uses thereof in therapeutic and diagnostic methods |
| EP2712870A1 (en) | 2012-09-27 | 2014-04-02 | Rheinische Friedrich-Wilhelms-Universität Bonn | Novel RIG-I ligands and methods for producing them |
| CA2892529C (en) | 2012-11-26 | 2023-04-25 | Moderna Therapeutics, Inc. | Terminally modified rna |
| JP2016501533A (ja) | 2012-12-14 | 2016-01-21 | ダイセルナ ファーマシューティカルズ， インコーポレイテッドＤｉｃｅｒｎａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 二本鎖ｒｎａによるｃｋａｐ５の特異的阻害に関する方法および組成物 |
| AU2014236250B2 (en) | 2013-03-14 | 2019-01-03 | Dicerna Pharmaceuticals, Inc. | Process for formulating an anionic agent |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| ES2905257T3 (es) | 2013-07-03 | 2022-04-07 | Dicerna Pharmaceuticals Inc | Métodos y composiciones para la inhibición específica de alfa-1 antitripsina mediante ARN bicatenario |
| WO2015020960A1 (en) | 2013-08-09 | 2015-02-12 | Novartis Ag | Novel lncrna polynucleotides |
| EP3052106A4 (en) | 2013-09-30 | 2017-07-19 | ModernaTX, Inc. | Polynucleotides encoding immune modulating polypeptides |
| EP3052521A1 (en) | 2013-10-03 | 2016-08-10 | Moderna Therapeutics, Inc. | Polynucleotides encoding low density lipoprotein receptor |
| CA2932904A1 (en) | 2013-12-06 | 2015-06-11 | Dicerna Pharmaceuticals, Inc. | Methods and compositions for the specific inhibition of transthyretin (ttr) by double-stranded rna |
| DK3087184T3 (da) | 2013-12-27 | 2019-07-29 | Dicerna Pharmaceuticals Inc | Fremgangsmåder og sammensætninger til specifik inhibering af glycolatoxidase (hao1) med dobbeltstrenget rna |
| ES2796923T3 (es) | 2014-10-10 | 2020-11-30 | Dicerna Pharmaceuticals Inc | Inhibición terapéutica de la lactato deshidrogenasa y agentes para esto |
| WO2016064347A1 (en) | 2014-10-22 | 2016-04-28 | Temasek Life Sciences Laboratory Limited | Terpene synthases from ylang ylang (cananga odorata var. fruticosa) |
| WO2016100401A1 (en) | 2014-12-15 | 2016-06-23 | Dicerna Pharmaceuticals, Inc. | Ligand-modified double-stranded nucleic acids |
| US10036017B2 (en) | 2015-02-17 | 2018-07-31 | Dicerna Pharmaceuticals, Inc. | Methods and compositions for the specific inhibition of complement component 5(C5) by double-stranded RNA |
| WO2016183009A2 (en) | 2015-05-08 | 2016-11-17 | Dicerna Pharmaceuticals, Inc. | Methods and compositions for the specific inhibition of antithrombin 3 (at3) by double-stranded rna |
| JP7073109B2 (ja) * | 2015-07-02 | 2022-05-23 | シティ・オブ・ホープ | ホスホロチオエート化オリゴデオキシヌクレオチドを含む化合物及び組成物、ならびにそれらの使用法 |
| PT3506909T (pt) | 2016-09-02 | 2022-08-16 | Dicerna Pharmaceuticals Inc | Análogos de 4¿-fosfato e oligonucleótidos compreendendo os mesmos |
| CN111201319A (zh) * | 2017-10-11 | 2020-05-26 | 日东电工株式会社 | 核酸分子表达的调节 |
| KR20230169413A (ko) | 2017-10-13 | 2023-12-15 | 노보 노르디스크 헬스 케어 악티엔게젤샤프트 | Ldha의 발현을 억제하기 위한 방법 및 조성물 |
| BR112020007476A2 (pt) | 2017-10-20 | 2020-10-27 | Dicerna Pharmaceuticals, Inc. | métodos para tratamento da infecção por hepatite b |
| CN111587116A (zh) | 2018-01-05 | 2020-08-25 | 迪克纳制药公司 | 降低β-连环蛋白和IDO表达以加强免疫疗法 |
| US11661603B2 (en) | 2018-01-16 | 2023-05-30 | Dicerna Pharmaceuticals, Inc. | Compositions and methods for inhibiting ALDH2 expression |
| KR20210033004A (ko) | 2018-07-13 | 2021-03-25 | 에프. 호프만-라 로슈 아게 | Rtel1의 발현을 조절하기 위한 올리고뉴클레오티드 |
| WO2020051231A1 (en) | 2018-09-04 | 2020-03-12 | H. Lee Moffitt Cancer Center & Research Institute Inc. | Use of delta-tocotrienol for treating cancer |
| WO2020142693A1 (en) * | 2019-01-04 | 2020-07-09 | Empirico Inc. | Treatment of thymic stromal lymphopoietin (tslp) related diseases by inhibition of long-form tslp transcripts |
| BR112021015651A2 (pt) | 2019-02-12 | 2021-10-05 | Dicerna Pharmaceuticals, Inc. | Métodos e composições para inibir a expressão de cyp27a1 |
| WO2020205473A1 (en) | 2019-03-29 | 2020-10-08 | Decerna Pharmaceuticals, Inc. | Compositions and methods for the treatment of kras associated diseases or disorders |
| BR112021019793A2 (pt) | 2019-04-04 | 2021-12-07 | Dicerna Pharmaceuticals Inc | Composições e métodos para inibir expressão de gene no sistema nervoso central |
| KR20220004675A (ko) | 2019-05-03 | 2022-01-11 | 다이서나 파마수이티컬, 인크. | 단축 센스 가닥을 갖는 이중 가닥 핵산 억제제 분자 |
| CN114867733A (zh) | 2019-08-30 | 2022-08-05 | 迪克纳制药公司 | 配体-2’-修饰核酸、其合成和其中间体化合物 |
| MX2022004032A (es) | 2019-10-02 | 2022-09-21 | Dicerna Pharmaceuticals Inc | Modificaciones químicas de arn interferente pequeño con mínimo contenido de flúor. |
| EP4081639A1 (en) | 2019-12-24 | 2022-11-02 | F. Hoffmann-La Roche AG | Pharmaceutical combination of a therapeutic oligonucleotide targeting hbv and a tlr7 agonist for treatment of hbv |
| WO2021130270A1 (en) | 2019-12-24 | 2021-07-01 | F. Hoffmann-La Roche Ag | Pharmaceutical combination of antiviral agents targeting hbv and/or an immune modulator for treatment of hbv |
| TWI870563B (zh) | 2020-03-18 | 2025-01-21 | 美商戴瑟納製藥股份有限公司 | 用於抑制angptl3表現之組合物及方法 |
| AU2021321289A1 (en) | 2020-08-04 | 2023-03-02 | Dicerna Pharmaceuticals, Inc. | Systemic delivery of oligonucleotides |
| TW202221120A (zh) | 2020-08-04 | 2022-06-01 | 美商黛瑟納製藥公司 | 用於治療代謝症候群之組成物及方法 |
| WO2022031847A2 (en) | 2020-08-04 | 2022-02-10 | Dicerna Pharmaceuticals Inc. | Compositions and methods for inhibiting plp1 expression |
| CA3190794A1 (en) | 2020-08-05 | 2022-02-10 | Soren Ottosen | Oligonucleotide treatment of hepatitis b patients |
| WO2022032288A1 (en) | 2020-08-05 | 2022-02-10 | Dicerna Pharmaceuticals, Inc. | Compositions and methods for inhibiting lpa expression |
| PE20250400A1 (es) | 2021-04-12 | 2025-02-11 | Dicerna Pharmaceuticals Inc | Composiciones y metodos para inhibir cetohexoquinasa |
| BR112023021109A2 (pt) | 2021-04-14 | 2023-12-12 | Dicerna Pharmaceuticals Inc | Composições e métodos para modular a expressão de pnpla3 |
| AU2022261359A1 (en) | 2021-04-19 | 2023-10-12 | Dicerna Pharmaceuticals, Inc. | Compositions and methods for inhibiting nuclear receptor subfamily 1 group h member 3 (nr1h3) expression |
| AU2022282579A1 (en) | 2021-05-28 | 2023-11-02 | Novo Nordisk A/S | Compositions and methods for inhibiting mitochondria amidoxime reducing component 1 (marc1) expression |
| EP4392556A1 (en) | 2021-08-25 | 2024-07-03 | Dicerna Pharmaceuticals, Inc. | Compositions and methods for inhibiting ?lpha-1 antitrypsin expression |
| WO2023083906A2 (en) | 2021-11-11 | 2023-05-19 | F. Hoffmann-La Roche Ag | Pharmaceutical combinations for treatment of hbv |
| US12234456B2 (en) | 2021-12-01 | 2025-02-25 | Dicerna Pharmaceuticals, Inc. | Compositions and methods for modulating APOC3 expression |
| JP2025512445A (ja) | 2022-04-15 | 2025-04-17 | ディセルナ ファーマシューティカルズ インコーポレイテッド | Ｓｃａｐ活性を調節するための組成物及び方法 |
| US20230416742A1 (en) | 2022-05-12 | 2023-12-28 | Dicerna Phrmaceuticals, Inc. | Compositions and methods for inhibiting mapt expression |
| IL316843A (en) | 2022-05-13 | 2025-01-01 | Dicerna Pharmaceuticals Inc | Compounds and methods for inhibiting SNCA deactivation |
| TWI868755B (zh) | 2022-06-24 | 2025-01-01 | 丹麥商諾佛 儂迪克股份有限公司 | 抑制跨膜絲胺酸蛋白酶６（ｔｍｐｒｓｓ６）表現的組成物及方法 |
| WO2024040041A1 (en) | 2022-08-15 | 2024-02-22 | Dicerna Pharmaceuticals, Inc. | Regulation of activity of rnai molecules |
| TW202430637A (zh) | 2022-11-16 | 2024-08-01 | 美商戴瑟納製藥股份有限公司 | Stat3靶向性寡核苷酸及其用途 |
| AR133386A1 (es) | 2023-07-28 | 2025-09-24 | Dicerna Pharmaceuticals Inc | Composiciones y métodos para la expresión del receptor del ligando de muerte programada (pd-l1) |
| WO2025054459A1 (en) | 2023-09-08 | 2025-03-13 | Dicerna Pharmaceuticals, Inc. | Rnai oligonucleotide conjugates |
| WO2025133951A1 (en) | 2023-12-21 | 2025-06-26 | Genevant Sciences Gmbh | Ionizable lipids suitable for lipid nanoparticles |
Family Cites Families (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030206887A1 (en) * | 1992-05-14 | 2003-11-06 | David Morrissey | RNA interference mediated inhibition of hepatitis B virus (HBV) using short interfering nucleic acid (siNA) |
| US5624803A (en) * | 1993-10-14 | 1997-04-29 | The Regents Of The University Of California | In vivo oligonucleotide generator, and methods of testing the binding affinity of triplex forming oligonucleotides derived therefrom |
| US5898031A (en) * | 1996-06-06 | 1999-04-27 | Isis Pharmaceuticals, Inc. | Oligoribonucleotides for cleaving RNA |
| CA2303299C (en) * | 1997-09-12 | 2016-02-23 | Exiqon A/S | Oligonucleotide analogues |
| US6506559B1 (en) * | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| WO2000044914A1 (en) * | 1999-01-28 | 2000-08-03 | Medical College Of Georgia Research Institute, Inc. | Composition and method for in vivo and in vitro attenuation of gene expression using double stranded rna |
| IL145778A0 (en) * | 1999-04-21 | 2002-07-25 | American Home Prod | Methods and compositions for inhibiting the function of polynucleotide sequences |
| WO2001004313A1 (en) | 1999-07-09 | 2001-01-18 | American Home Products Corporation | Methods and compositions for preventing the formation of aberrant rna during transcription of a plasmid sequence |
| US7829693B2 (en) * | 1999-11-24 | 2010-11-09 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of a target gene |
| DE10160151A1 (de) | 2001-01-09 | 2003-06-26 | Ribopharma Ag | Verfahren zur Hemmung der Expression eines vorgegebenen Zielgens |
| US20050032733A1 (en) * | 2001-05-18 | 2005-02-10 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SiNA) |
| US20050020525A1 (en) * | 2002-02-20 | 2005-01-27 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
| US20050233329A1 (en) * | 2002-02-20 | 2005-10-20 | Sirna Therapeutics, Inc. | Inhibition of gene expression using duplex forming oligonucleotides |
| US8202979B2 (en) * | 2002-02-20 | 2012-06-19 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid |
| US20070026394A1 (en) * | 2000-02-11 | 2007-02-01 | Lawrence Blatt | Modulation of gene expression associated with inflammation proliferation and neurite outgrowth using nucleic acid based technologies |
| US8202846B2 (en) * | 2000-03-16 | 2012-06-19 | Cold Spring Harbor Laboratory | Methods and compositions for RNA interference |
| IL151928A0 (en) * | 2000-03-30 | 2003-04-10 | Whitehead Biomedical Inst | Rna sequence-specific mediators of rna interference |
| WO2002004321A2 (de) | 2000-07-10 | 2002-01-17 | Aloys Wobben | Vorrichtung zum handhaben von stückgütern |
| BRPI0115814B8 (pt) * | 2000-12-01 | 2021-05-25 | Europaeisches Laboratorium Fuer Molekularbiologie Embl | moléculas de rna de filamento duplo, seu método de preparação e composição farmacêutica compreendendo as mesmas |
| CA2369944A1 (en) * | 2001-01-31 | 2002-07-31 | Nucleonics Inc. | Use of post-transcriptional gene silencing for identifying nucleic acid sequences that modulate the function of a cell |
| US20060287267A1 (en) * | 2001-05-18 | 2006-12-21 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of respiratory syncytial virus (RSV) expression using short interfering nucleic acid (siNA) |
| US20050079610A1 (en) * | 2001-05-18 | 2005-04-14 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of Fos gene expression using short interfering nucleic acid (siNA) |
| US20060217331A1 (en) * | 2001-05-18 | 2006-09-28 | Sirna Therapeutics, Inc. | Chemically modified double stranded nucleic acid molecules that mediate RNA interference |
| EP1627061B1 (en) | 2001-05-18 | 2009-08-12 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA) |
| US20050282188A1 (en) * | 2001-05-18 | 2005-12-22 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA) |
| CA2921821A1 (en) * | 2001-07-12 | 2003-01-23 | University Of Massachusetts | In vivo production of small interfering rnas that mediate gene silencing |
| AU2002343792A1 (en) * | 2001-11-28 | 2003-06-10 | Center For Advanced Science And Technology Incubation, Ltd. | siRNA EXPRESSION SYSTEM AND PROCESS FOR PRODUCING FUNCTIONAL GENE-KNOCKDOWN CELLS AND THE LIKE USING THE SAME |
| DE10202419A1 (de) * | 2002-01-22 | 2003-08-07 | Ribopharma Ag | Verfahren zur Hemmung der Expression eines durch eine Chromosomen-Aberration entstandenen Zielgens |
| US20040014956A1 (en) * | 2002-02-01 | 2004-01-22 | Sequitur, Inc. | Double-stranded oligonucleotides |
| US20060009409A1 (en) * | 2002-02-01 | 2006-01-12 | Woolf Tod M | Double-stranded oligonucleotides |
| CA2479530A1 (en) | 2002-03-20 | 2003-10-02 | Massachusetts Institute Of Technology | Hiv therapeutic |
| US20040180438A1 (en) * | 2002-04-26 | 2004-09-16 | Pachuk Catherine J. | Methods and compositions for silencing genes without inducing toxicity |
| US6890719B2 (en) | 2002-05-10 | 2005-05-10 | The Board Of Trustess Of The University Of Illinois | Fluorescence based biosensor |
| US7148342B2 (en) * | 2002-07-24 | 2006-12-12 | The Trustees Of The University Of Pennyslvania | Compositions and methods for sirna inhibition of angiogenesis |
| US20050058982A1 (en) | 2002-07-26 | 2005-03-17 | Chiron Corporation | Modified small interfering RNA molecules and methods of use |
| WO2004011624A2 (en) * | 2002-07-31 | 2004-02-05 | Nucleonics, Inc. | Double stranded rna structures and constructs, and methods for generating and using the same |
| EP3222725A1 (en) * | 2002-08-05 | 2017-09-27 | Silence Therapeutics GmbH | Further novel forms of interfering rna molecules |
| US20040023390A1 (en) * | 2002-08-05 | 2004-02-05 | Davidson Beverly L. | SiRNA-mediated gene silencing with viral vectors |
| HUE032289T2 (en) * | 2002-08-05 | 2017-09-28 | Silence Therapeutics Gmbh | Other new forms of interfering RNA molecules |
| US20050042646A1 (en) * | 2002-08-05 | 2005-02-24 | Davidson Beverly L. | RNA interference suppresion of neurodegenerative diseases and methods of use thereof |
| WO2004014933A1 (en) * | 2002-08-07 | 2004-02-19 | University Of Massachusetts | Compositions for rna interference and methods of use thereof |
| EP1546344A4 (en) * | 2002-09-18 | 2007-10-03 | Isis Pharmaceuticals Inc | EFFICIENT PRODUCTION OF TARGET RNAS USING SINGLE AND DOUBLE-STRONG OLIGOMER COMPOUNDS |
| AU2003277005A1 (en) | 2002-09-26 | 2004-04-19 | The Regents Of The University Of California | Conditional gene expression using rnai |
| US20060035344A1 (en) | 2002-10-18 | 2006-02-16 | Pachuk Catherine J | Double-stranded rna structures and constructs, and methods for generating and using the same |
| AU2003290596B2 (en) * | 2002-11-05 | 2011-05-12 | Isis Pharmaceuticals, Inc. | Sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation |
| US20040248299A1 (en) * | 2002-12-27 | 2004-12-09 | Sumedha Jayasena | RNA interference |
| WO2004065600A2 (en) * | 2003-01-17 | 2004-08-05 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Rna interference by palindromic or modified rna molecules |
| WO2004076629A2 (en) | 2003-02-27 | 2004-09-10 | Nucleonics Inc. | METHODS AND CONSTRUCTS FOR EVALUATION OF RNAi TARGETS AND EFFECTOR MOLECULES |
| WO2004094654A2 (en) * | 2003-04-22 | 2004-11-04 | Nucleonics, Inc. | Transfection kinetics and structural promoters |
| US20040224405A1 (en) * | 2003-05-06 | 2004-11-11 | Dharmacon Inc. | siRNA induced systemic gene silencing in mammalian systems |
| US7750144B2 (en) * | 2003-06-02 | 2010-07-06 | University Of Massachusetts | Methods and compositions for enhancing the efficacy and specificity of RNA silencing |
| US7595306B2 (en) * | 2003-06-09 | 2009-09-29 | Alnylam Pharmaceuticals Inc | Method of treating neurodegenerative disease |
| CA3040025C (en) | 2003-06-12 | 2023-01-10 | Alnylam Pharmaceuticals, Inc. | Conserved hbv and hcv sequences useful for gene silencing |
| CA2536026A1 (en) | 2003-08-22 | 2005-05-06 | Nucleonics Inc. | Eukariotic expression systems for expression of inhibitory rna in multiple intracellular compartments |
| GB0323270D0 (en) | 2003-10-04 | 2003-11-05 | Bodycage Ltd | Stirrup |
| US20070265220A1 (en) * | 2004-03-15 | 2007-11-15 | City Of Hope | Methods and compositions for the specific inhibition of gene expression by double-stranded RNA |
| AU2005222965B8 (en) * | 2004-03-15 | 2010-07-01 | City Of Hope | Methods and compositions for the specific inhibition of gene expression by double-stranded RNA |
| EP1765416A4 (en) * | 2004-06-03 | 2010-03-24 | Isis Pharmaceuticals Inc | DOUBLE-STRONG COMPOSITIONS WITH DIFFERENTLY MODIFIED STRANDS FOR USE IN GENE MODULATION |
| US8394947B2 (en) * | 2004-06-03 | 2013-03-12 | Isis Pharmaceuticals, Inc. | Positionally modified siRNA constructs |
| ES2594083T3 (es) * | 2004-09-28 | 2016-12-15 | Quark Pharmaceuticals, Inc. | Oligorribonucleótidos y métodos de uso de los mismos para tratamiento de la alopecia, insuficiencia renal aguda y otras enfermedades |
-
2007
- 2007-05-01 US US11/797,216 patent/US20070265220A1/en not_active Abandoned
-
2008
- 2008-04-11 BR BRPI0811475 patent/BRPI0811475A2/pt not_active IP Right Cessation
- 2008-04-11 EP EP08742798A patent/EP2155772A4/en not_active Withdrawn
- 2008-04-11 WO PCT/US2008/004726 patent/WO2008136902A1/en not_active Ceased
- 2008-04-11 JP JP2010506206A patent/JP2010525813A/ja active Pending
- 2008-04-11 CA CA 2685453 patent/CA2685453A1/en not_active Abandoned
- 2008-04-11 CN CN200880021385A patent/CN101848923A/zh active Pending
- 2008-04-11 AU AU2008246307A patent/AU2008246307A1/en not_active Abandoned
- 2008-06-20 US US12/143,002 patent/US20090043085A1/en not_active Abandoned
- 2008-06-20 US US12/143,006 patent/US20090035854A1/en not_active Abandoned
- 2008-06-20 US US12/143,009 patent/US20090036661A1/en not_active Abandoned
- 2008-06-20 US US12/143,027 patent/US20090029466A1/en not_active Abandoned
- 2008-06-20 US US12/143,024 patent/US20090029936A1/en not_active Abandoned
-
2009
- 2009-11-25 ZA ZA200908342A patent/ZA200908342B/xx unknown
-
2010
- 2010-06-01 US US12/791,369 patent/US20100240734A1/en not_active Abandoned
-
2012
- 2012-06-08 US US13/491,937 patent/US8883996B2/en active Active
-
2014
- 2014-11-10 US US14/537,578 patent/US9441227B2/en active Active
-
2016
- 2016-09-08 US US15/259,174 patent/US9873875B2/en active Active
-
2017
- 2017-12-21 US US15/849,887 patent/US10233450B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010525813A5 (enExample) | ||
| JP2011502502A5 (enExample) | ||
| NZ598943A (en) | Hbv antisense inhibitors | |
| WO2005089287A3 (en) | Methods and compositions for the specific inhibition of gene expression by double-stranded rna | |
| CN113943764B (zh) | 一种制备双链rna的方法 | |
| JP2017093448A5 (enExample) | ||
| JP2006526394A5 (enExample) | ||
| JP2008283975A5 (enExample) | ||
| RU2017117510A (ru) | Редактирование целевой рнк | |
| JP2007532100A5 (enExample) | ||
| JP2011500092A5 (enExample) | ||
| JP2007503474A5 (enExample) | ||
| JP2005517452A5 (enExample) | ||
| JP2012507984A5 (enExample) | ||
| JP2012514451A5 (enExample) | ||
| WO2010090857A3 (en) | Methods for amplifying hepatitis c virus nucleic acids | |
| WO2005049851A3 (en) | Methods, articles, and compositions for identifying oligonucleotides | |
| WO2010006973A3 (en) | Compositions and methods for inhibiting expression of tgf-beta receptor genes | |
| JP2011512153A5 (enExample) | ||
| Wulf et al. | Chemical capping improves template switching and enhances sequencing of small RNAs | |
| Xu et al. | TGIRT-seq protocol for the comprehensive profiling of coding and non-coding RNA biotypes in cellular, extracellular vesicle, and plasma RNAs | |
| JP2013524841A (ja) | 一本鎖オーバーハングを有する二本鎖核酸を生成するための方法 | |
| JP6069314B2 (ja) | 長鎖核酸分子の大規模合成方法 | |
| JP2006521824A5 (enExample) | ||
| WO2023167276A1 (ja) | キャップ化ｒｎａ及びその製造方法並びにタンパク質の製造装置及びタンパク質の製造方法 |